DGAP-News: Asklepios Kliniken
/ Key word(s): Merger/Joint Venture
26.05.2020 / 13:01
The issuer is solely responsible for the content of this announcement.
Joint venture between Asklepios and RHÖN founder Eugen Münch cleared by Bundeskartellamt
Hamburg, May 26, 2020. On May 26, 2020, Asklepios Kliniken GmbH & Co. KGaA obtained approval from the Bundeskartellamt to pool the joint shares in RHÖN-KLINIKUM AG (RKA) held with RHÖN founder Eugen Münch in a joint venture and for the voluntary public takeover offer for all outstanding shares in RKA. Approval was granted in the first investigation phase, without conditions or requirements.
“The fact that the Bundeskartellamt gave its approval at such an early stage despite the exceptional situation due to the corona pandemic is an important milestone for our partnership with RHÖN founder Eugen Münch and for RHÖN’s future,” said Kai Hankeln, CEO of Asklepios Group. “On completion of the voluntary takeover offer, we can start straightaway with making our vision for healthcare in Germany a reality. This will benefit the hospitals under the auspices of the Asklepios/RHÖN Group, their workforces and, in particular, their patients.”
Eugen Münch, RHÖN’s founder and Chairman of the Supervisory Board, added, “In the present situation, RHÖN is facing major challenges along with the sector as a whole. The cooperation with Asklepios resolves the deadlock among RHÖN’s shareholders and generates important new impetus. Together with Asklepios, we can stabilize RHÖN’s long-term earnings potential and performance in a difficult market environment. The approval now granted by the Bundeskartellamt sends a clear message. The Asklepios/RHÖN Group secures our company’s future.”
At the end of February, Asklepios and Eugen Münch had announced their decision to pool their shares in RKA in a joint venture. Münch is contributing approximately 7.6% of RHÖN shares to the joint venture through HCM SE, which he controls, and is, together with his wife, selling approximately 12.4% of RHÖN shares to Asklepios, which will likewise contribute these shares to the joint venture. Asklepios published the offer document for the voluntary public takeover offer to all RKA shareholders on April 8, 2020. Approval of the transaction by the Bundeskartellamt means that the condition precedent is satisfied for the joint venture and for completion of the offer, which is not subject to a minimum acceptance threshold.
Even before commencement of the offer phase, the Asklepios-Münch joint venture already secured – subject to Bundeskartellamt approval – a voting rights majority in RHÖN of just over 50%. Due to the decision of RHÖN’s Board of Management to convene an extraordinary general meeting, the acceptance period for the takeover offer is expected to run to June 17, 2020.
Asklepios Kliniken is one of the leading private operators of hospitals and healthcare facilities in Germany. The hospital group stands for highly qualified care for its patients, with a clear commitment to medical quality, innovation and social responsibility. On this basis, Asklepios has grown dynamically since it was founded almost 35 years ago. The Group currently has around 160 healthcare facilities throughout Germany, including acute care hospitals for all levels of care, specialist clinics, psychiatric and forensic facilities, rehabilitation clinics, nursing homes and medical service centres. In the 2019 financial year, 2.5 million patients were treated at the Asklepios Group’s facilities. The company has more than 49,000 employees.
26.05.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.